The "tricky business" of identifying mechanisms of resistance to anti-PD-1

James S. Wilmott; Helen Rizos; Richard A. Scolyer; Georgina V. Long

doi:10.1158/1078-0432.CCR-17-0669

The "tricky business" of identifying mechanisms of resistance to anti-PD-1

James S. Wilmott, Helen Rizos, Richard A. Scolyer, Georgina V. Long^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

5 Citations (Scopus)

Abstract

Resistance to immune checkpoint inhibitors can vary between patients and among metastases. Understanding the genomic, transcriptomic, and microenvironmental factors that contribute to this variability will reveal the mechanisms that tumors utilize to evade the therapeutic effects of checkpoint inhibitor immunotherapies and will enable us to develop strategies to overcome them.

Original language	English
Pages (from-to)	2921-2923
Number of pages	3
Journal	Clinical Cancer Research
Volume	23
Issue number	12
DOIs	https://doi.org/10.1158/1078-0432.CCR-17-0669
Publication status	Published - 15 Jun 2017

Access to Document

10.1158/1078-0432.CCR-17-0669

Cite this

@article{c88027ddebda4f8a83b6bec2cc37b953,

title = "The {"}tricky business{"} of identifying mechanisms of resistance to anti-PD-1",

abstract = "Resistance to immune checkpoint inhibitors can vary between patients and among metastases. Understanding the genomic, transcriptomic, and microenvironmental factors that contribute to this variability will reveal the mechanisms that tumors utilize to evade the therapeutic effects of checkpoint inhibitor immunotherapies and will enable us to develop strategies to overcome them.",

author = "Wilmott, {James S.} and Helen Rizos and Scolyer, {Richard A.} and Long, {Georgina V.}",

year = "2017",

month = jun,

day = "15",

doi = "10.1158/1078-0432.CCR-17-0669",

language = "English",

volume = "23",

pages = "2921--2923",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "AMER ASSOC CANCER RESEARCH",

number = "12",

}

TY - JOUR

T1 - The "tricky business" of identifying mechanisms of resistance to anti-PD-1

AU - Wilmott, James S.

AU - Rizos, Helen

AU - Scolyer, Richard A.

AU - Long, Georgina V.

PY - 2017/6/15

Y1 - 2017/6/15

N2 - Resistance to immune checkpoint inhibitors can vary between patients and among metastases. Understanding the genomic, transcriptomic, and microenvironmental factors that contribute to this variability will reveal the mechanisms that tumors utilize to evade the therapeutic effects of checkpoint inhibitor immunotherapies and will enable us to develop strategies to overcome them.

AB - Resistance to immune checkpoint inhibitors can vary between patients and among metastases. Understanding the genomic, transcriptomic, and microenvironmental factors that contribute to this variability will reveal the mechanisms that tumors utilize to evade the therapeutic effects of checkpoint inhibitor immunotherapies and will enable us to develop strategies to overcome them.

UR - http://www.scopus.com/inward/record.url?scp=85020800115&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-17-0669

DO - 10.1158/1078-0432.CCR-17-0669

M3 - Review article

C2 - 28468948

AN - SCOPUS:85020800115

SN - 1078-0432

VL - 23

SP - 2921

EP - 2923

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 12

ER -

The "tricky business" of identifying mechanisms of resistance to anti-PD-1

Abstract

Access to Document

Other files and links

Fingerprint

Cite this